AI assistant
GlaxoSmithKline PLC Director's Dealing 2025
5262_dirs_2025-12-01_1269f0d5-1a54-4402-a2dd-52b9278d5249.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 7266J
GSK PLC
01 December 2025
GSK plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.19 | 643 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2025-11-28
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
David Redfern
b)
Position/status
President, Corporate Development
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.19 | 643 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2025-11-28
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.19 | 643 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2025-11-28
f)
Place of the transaction
London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFSSFDFEISEDE